How Should we Treat Patients with Locally Advanced Prostate Cancer?

European Urology, Supplement

Volumn 2, Issue 9, 2003, Pages 14-22

  Mason, Malcolm ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Adjuvant; Bicalutamide; Castration; Goserelin; Hormone therapy; Locally advanced; Prostate cancer; Quality of life; Radiotherapy

Indexed keywords

BICALUTAMIDE; GOSERELIN;

BONE DENSITY; BONE MINERAL; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONFERENCE PAPER; DOSE RESPONSE; GYNECOMASTIA; HUMAN; MASTALGIA; MUSCLE MASS; PHYSICAL CAPACITY; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUALITY OF LIFE; SEXUAL BEHAVIOR; SURGICAL TECHNIQUE; TREATMENT PLANNING;

EID: 0345168222     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2003.10.001     Document Type: Conference Paper

References (29)

1. Johansson J-E, Holmberg L, Johansson S, Bergström R, Adami H-O. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997:277:467-71.
2. Schmid H-P, Adolfsson J, Aus G. Active monitoring (deferred treatment or watchful waiting) in the treatment of prostate cancer. Eur Urol 2001;40:488-94.
3. Zagars GK, Pollack A, Smith LG. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1999;44:809-19.
4. Roach III M, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry R, et al. Long-term survival after radiotherapy alone: Radiation Therapy Oncology Group prostate cancer trials. J Urol 1999;161:864-8.
5. Pilepich MV, Krall JM, Al-Sarraf M, John MJ, Scotte Doggett RL, Sause WT, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995;45:616-23.
6. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-52.
7. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group protocol 85-31. J Clin Oncol 1997;15:1013-21.
8. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff R-O, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
9. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff R-O, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103-8.
10. Pilepich MV, Winter K, Lawton C, Krisch RE, Wolkov H, Movsas B, et al. Phase III trial of androgen suppression adjuvant to definitive radiotherapy. Long term results of RTOG study 85-31. Proc Am Soc Clin Oncol 2003:22:381.
11. Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, et al. Updated results of the Phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49:937-46.
12. Granfors T, Modig H, Damber J-E, Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol 1998;159:2030-4.
13. Horwitz EM, Winter K, Hanks GE, Lawton CA, Russell AH, Machtay M. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 2001;49:947-56.
14. Hanks GE, Lu J, Machtay V, Venkatesan V, Pinover W, Byhardt R, et al. RTOG protocol 92-02: a phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Proc Am Soc Clin Oncol 2000;19:327a.
15. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 1997:79:235-46.
16. Kirk D on behalf of the Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate vs. deferred hormone treatment for prostate cancer: how safe is androgen deprivation? BJU Int 2000;86(Suppl 3):220.
17. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781-8.
18. Messing E, Manola J, Sarosdy M, Wilding G, Crawford ED. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer: results at 10 years of EST 3886. J Urol 2003;169:396.
19. Kirby R. Treatment options for early prostate cancer. Urology 1998;52:948-62.
20. Fonseca R, Rajkumar SV, White WL, Tefferi A, Hoagland HC. Anemia after orchiectomy. Am J Hematol 1998;59:230-3.
21. Ross RW, Small EJ. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 2002;167:1952-6.
22. Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mactaggart PN, et al. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int 2002;90:427-32.
23. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Baert L, Tammela T, et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998;51:389-96.
24. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TLJ, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000;164:1579-82.
25. Sieber PR, Keiller DL, Kahnoski RJ, Garcia-Vargas JE, Gallo J, McFadden S. Bone mineral density is maintained during bicalutamide ('Casodex') treatment. Proc Am Soc Clin Oncol 2002;21:196a.
26. See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, et al. on behalf of the Casodex Early Prostate Cancer Trialist Group. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer program. J Urol 2002;168:429-35.
27. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097-105.
28. Lilleby W, Fossa SD, Waehre HR, Olsen DR. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int J Radiat Oncol Biol Phys 1999;43:735-43.
29. Fellows GJ, Clark PB, Beynon LL, Boreham J, Keen C, Parkinson MC, et al. Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy, or combined treatment. A Medical Research Council Study. Urological Cancer Working Party-Sub-group on Prostatic Cancer. Br J Urol 1992;70:304-9.